drugset / Trial / NCT00444275

Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients

NCT00444275

Phase 4 Completed 3029 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy of three different long-term treatment strategies of reflux disease in primary care setting.

Timeline

Start
2007-03
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 20 mg
Subject Esomeprazole Small molecule 40 mg
Subject Xolaam® Unknown